Trifluoperazine versus low-potency first-generation antipsychotic drugs for schizophrenia

Cochrane Database of Systematic Reviews

Volumn 2014, Issue 7, 2014, Pages

  Tardy, Magdolna ^a   Dold, Markus ^a   Engel, Rolf R ^b   Leucht, Stefan ^c  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

LOW POTENCY FIRST GENERATION ANTIPSYCHOTIC DRUG; NEUROLEPTIC AGENT; TRIFLUOPERAZINE; UNCLASSIFIED DRUG;

AKATHISIA; AKINESIA; ATYPICAL SEIZURE; BLURRED VISION; COORDINATION DISORDER; DATA ANALYSIS; DATA EXTRACTION; DATA SYNTHESIS; DECREASED APPETITE; DIZZINESS; DROWSINESS; DRUG POTENCY; DRUG RESPONSE; DYSKINESIA; FAINTNESS; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERSALIVATION; INSOMNIA; INTENTION TO TREAT ANALYSIS; LETHARGY; MENTAL PATIENT; MOTOR DYSFUNCTION; MUSCLE WEAKNESS; OUTCOME ASSESSMENT; PATIENT SATISFACTION; POLYDIPSIA; POLYURIA; PRIORITY JOURNAL; PUBLISHING; QUALITY CONTROL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RIGOR; SCHIZOPHRENIA; SEIZURE; SKIN DISEASE; SLURRED SPEECH; STUDY DESIGN; SYSTEMATIC REVIEW; META ANALYSIS; PATIENT DROPOUTS; STATISTICS AND NUMERICAL DATA;

ANTIPSYCHOTIC AGENTS; HUMANS; PATIENT DROPOUTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCHIZOPHRENIA; TRIFLUOPERAZINE;

EID: 84922394945     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD009396.pub2     Document Type: Review

References (82)

1. Coons WH, Boyd BA, White JG. Chlorpromazine, trifluoperazine and placebo with long-term mental hospital patients. Canadian Psychiatric Association Journal 1962;7(4):159-63.
2. Hanlon TE, Michaux MH, Ota KY, Shaffer JW, Kurland AA. The comparative effectiveness of eight phenthiazines. Psychopharmacologia 1965;7:89-106.
3. Hollister LE, Erickson GV, Motzentecker FP. Trifluoperazine in chronic psychiatric patients. Journal of Clinical and Experimental Psychopathology 19610;21:15-23.
4. Leff JP, Hirsch SR, Gaind R, Rohde PD, Stevens BC. Life events and maintenance therapy in schizophrenic relapse. British Journal of Psychiatry 1973;123:659-60.
5. Leff JP, Wing JK. Trial of maintenance therapy in schizophrenia. British Medical Journal 1971;3:599-604.
6. Morton MR. A study of the withdrawal of chlorpromazine or trifluoperazine in chronic schizophrenia. American Journal of Psychiatry 1968;124(11):1585-8.
7. Reardon JD, Abrams S. Acute paranoid schizophrenia (treatment with chlorpromazine, trifluoperazine and placebo). Diseases of the Nervous System 1966;27:265-70.
8. Schiele BC, Vestre ND, Stein KE. A comparison of thioridazine, trifluoperazine, chlorpromazine, and placebo: a double-blind controlled study on the treatment of chronic hospitalized, schizophrenic patients. Journal of Clinical and Experimental Psychopathology 1961;22:151-62.
9. Barsa JA, Saunders JC, Kline NS. Trifluoperazine in the treatment of chronic schizophrenics. American Journal of Psychiatry 1959;115(9):812.
10. Casey JF, Hollister LE, Klett CJ, Lasky JJ, Caffey EM. Combined drug therapy of chronic schizophrenics. Controlled evaluation of placebo, dextro-amphetamine, imipramine, isocarboxazid and trifluoperazine added to maintenance doses of chlorpromazine. American Journal of Psychiatry 1961;117:997-1003.
11. Childers RT, Therrien R. A comparison of the effectiveness of trifluoperazine and chlorpromazine in schizophrenia. American Journal of Psychiatry 1964;118:552-4.
12. Crane GE. High doses of trifluperazine and tardive dyskinesia. Archives of Neurology 1970;22(2):176-80.
13. de Jong J. Efficacy of phenothiazines without antiparkinson drugs. Diseases of the Nervous System 1965;26(11):702-4.
14. DeWolfe AS, Barrell RP, London L, Spaner FE. Prolixin enanthate and thorazine-stelazine regimens in the treatment of schizophrenic patients. An experimental evaluation. Psychosomatics 1971;12(3):186-90.
15. Eitan N, Levin Y, Ben Artzi E, Levy A, Neumann M. Effects of antipsychotic drugs on memory functions of schizophrenic patients. Acta Psychiatrica Scandinavica 1992;85(1):74-6.
16. Freyhan FA. Therapeutic implications of differential effects of new phenothiazine compounds. American Journal of Psychiatry 1959;116:577-85.
17. Gardos G, Finnerty RJ, Cole JO. Thiothixene and trifluoperazine in a step system. Psychosomatics 1970;11(1):36-40.
18. Gillis JS. The effects of selected antipsychotic drugs of human judgment. Current Therapeutic Research, Clinical and Experimental 1977;21(2):224-32.
19. Hamilton M, Hordern A, Waldrop FN, Lofft J. A controlled trial on the value of prochlorperazine, trifluoperazine and intensive group treatment. British Journal of Psychiatry 1963;109:510-22.
20. Hershon HI, Kennedy PF, McGuire RJ. Persistence of extra-pyramidal disorders and psychiatric relapse after withdrawal of long-term phenothiazine therapy. British Journal of Psychiatry 1972;120(554):41-50.
21. Jones IH, Pikler N. Effects of chlorpromazine and trifluoperazine on the activity of chronic schizophrenics. British Journal of Psychiatry 1971;119(552):545-6.
22. Marjerrison G, Hrychuk W, Varsanyi EI. A comparison of two butyrophenones with trifluoperazine. Canadian Psychiatric Association Journal 1966;11(1):26-30.
23. Platz AR, Klett CJ, Caffey EM. Selective drug action related to chronic schizophrenic subtype (A comparative study of carphenazine, chlorpromazine, and trifluoperazine). Diseases of the Nervous System 1967;28(9):601-5.
24. Prien RF, Levine J, Cole JO. High dose therapy in chronic schizophrenia - trifuoperazine. Proceedings of the 121st Annual Meeting of the American Psychiatric Association; 1968 May 13-17; Boston, Massachusetts, USA. 1968.
25. Prien RF, Levine J, Cole JO. High dose trifluoperazine therapy in chronic schizophrenia. American Journal of Psychiatry 1969;126(3):305-13.
26. Rudy L, Rinaldi E, Himwich H, Tuteur W, Glotzer J. Trifluoperazine in the treatment of psychotic patients. American Journal of Psychiatry 1958;115:364-5.
27. Smith JA, Christian D, Rutherford A, Mansfield E. A comparison of triflupromazine (vesprin), chlorpromazine and PLACEBO in 85 chronic patients. American Journal of Psychiatry 1958;115:253-4.
28. Spiegel DE, Keith-Spiegel P. The effects of carphenazine, trifluoperazine and chlorpromazine on ward behavior, physiological functioning and psychological test scores in chronic schizophrenic patients. Journal of Nervous and Mental Diseases 1967;144(2):111-6.
29. Teja JS, Grey WH, Clum JM, Warren C. Tranquilizers or anti-depressants for chronic schizophrenics: a long term study. Australian and New Zealand Journal of Psychiatry 1975;9(4):241-7.
30. Terminska K, Mrowiec W. Comparison of influence of perazine, fluphenazine, trifluoroperazine, chloropromazine and haloperidol on primary and deficit schizophrenic symptoms in patients first hospitalized because of paranoid schizophrenia [Badanie porownawcze wplywu perazyny, flufenazyny, trifluoroperazyny, chloropromazny i haloperydolu na objawy pierwotne i deficytowe pierwszego zachorowania na schizofrenie paranoidalna]. Psychiatria Polska 1989;23(1):24-30.
31. Vestre ND, Schiele BC. Differential drug effects of two phenothiazines (A controlled comparison of thioridazine and trifluoperazine in chronic schizophrenics). Diseases of the Nervous System 1970;31(12):821-5.
32. Vinar O, Taussigova D. Clinical experience with trifluoperazine. Activitas Nervosa Superior 1968;8:447-51.
33. Welbel L. Differences in the clinical effect of various neuroleptics [Roznice w dziallaniu klinicznym niektorych neuroleptykow]. Psychiatria Polska 1980;14(2):113-8.
34. Weston FK, Loftus AP. A terminal double-blind trial of tri-fluoperazine ("stelazine") in chronic schizophrenia. Medical Journal of Australia 1961;48(1):776-80.
35. Wilson IC, McKay J, Sandifer MG. A double-blind trial to investigate the effects of thorazine (largactil, chlorpromazine), compazine (stemetil, prochlorperazine) and stelazine (trifluoperazine) in paranoid schizophrenia. Journal of Mental Science 1961;107:90-9.
36. Altman DG, Bland JM. Detecting skewness from summary information. BMJ 1996;313:1200.
37. Andreasen NC, Pressler M, Nopoulos P, Miller D, Ho BC. Antipsychotic dose equivalents and dose-years: a standardized method for comparing exposure to different drugs. Biological Psychiatry 2010;67:255-62.
38. Berger M. Psychische Erkrankungen. Klinik und Therapie. 2nd Edition. München: Urban & Fischer, 2003.
39. Bland JM, Kerry SM. Statistics notes. Trials randomised in clusters. BMJ 1997;315:600.
40. Boissel JP, Cucherat M, Li W, Chatellier G, Gueyffier F, Buyse M, et al.The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use. Therapie 1999;54(4):405-11.
41. Campbell M, Grimshaw J, Steen N. Sample size calculations for cluster randomised trials. Changing Professional Practice in Europe Group (EU BIOMED II Concerted Action). Journal of Health Services Research and Policy 2000;5:12-6.
42. Carpenter WT, Buchanan RW. Schizophrenia. New England Journal of Medicine 1994;330:681-90.
43. Davis JM. Overview: maintenance therapy in psychiatry: I. Schizophrenia. American Journal of Psychiatry 1975;132(12):1237-45.
44. Davis JM, Barter JT, Kane JM. Antipsychotic drugs. Comprehensive Textbook of Psychiatry. Williams and Wilkins, 1989.
45. Deeks J. Issues in the selection for meta-analyses of binary data. Proceedings of the 8th International Cochrane Colloquium; 2000 Oct 25-28th; Cape Town, South Africa. Cape Town, 2000.
46. Der-Simonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials 1986;7:177-88.
47. Divine GW, Brown JT, Frazer LM. The unit of analysis error in studies about physicians' patient care behavior. Journal of General Internal Medicine 1992;7:623-9.
48. Egger M, Davey-Smith G, Schneider M, Minder CSO. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;13:629-34.
49. Elbourne DR, Altman DG, Higgins JP, Curtin F, Worthington HV, Vail A. Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology 2002;31:140-9.
50. Falkai P, Wobrock T, Lieberman J. World Federation of Societies of Biological Psychiatry (WFSBP) - Guidelines for biological treatment of schizophrenia, part 1: Acute treatment of schizophrenia. World Journal of Biololgical Psychiatry 2005;6:132-91.
51. Furukawa TA, Akechi T, Wagenpfeil S, Leucht S. Relative indices of treatment effect may be constant across different definitions of response in schizophrenia trials. Schizophrenia Research 2011;126:212-9.
52. Gaebel W, Falkai P, Weinmann S. Behandlungsleitlinie Schizophrenie. Darmstadt: Steinkopff, 2006.
53. Gulliford MC, Ukoumunne OC, Chinn S. Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology 1999;149:876-83.
54. Haase HJ. Dosierung der Neuroleptika. Ein Leitfaden für Klinik und Praxis unter besonderer Berücksichtigung psychotisch Kranker. Erlangen: Perimed Fachbuch-Verlagsgesellschaft, 1983.
55. Hathaway, SR, McKinley, JC. A multiphasic personality schedule (Minnesota). Journal of Psychology 1940;10:249-54.
56. Higgins JPT, Deeks JJ, Altman DG (editors). Chapter 16: Special topics in statistics. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 (updated September 2008). The Cochrane Collaboration, 2008:481-524.
57. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org..
58. Jones PB, Barnes TRE, Davies L. Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia - cost utility of the latest antipsychotic drugs in schizophrenia study (CUtLASS 1). Archives of General Psychiatry 2006;63:1079-86.
59. Kay SR, Opler LA, Fiszbein A. Positive and Negative Syndrome Scale (PANSS) manual. North Tonawanda (NY): Multi-Health Systems, 1986.
60. Klein DF, Davis JM. Diagnosis and Drug Treatment of Psychiatric Disorders. Baltimore: Williams and Wilkins, 1969.
61. Lehman AF, Lieberman J.A, Dixon LB. Practice guideline for the treatment of patients with schizophrenia, second edition. American Journal of Psychiatry 2004;161:1-56.
62. Leon AC, Mallinckrodt CH, Chuang-Stein C, Archibald DG, Archer GE, Chartier K. Attrition in randomized controlled clinical trials: methodological issues in psychopharmacology. Biological Psychiatry 2006;59:1001-5.
63. Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R. What does the PANSS mean?. Schizophrenia Research 2005;79:231-8.
64. Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R. Clinical implications of brief psychiatric rating scale scores. British Journal of Psychiatry 2005;187:366-71.
65. Leucht S, Corves C, Arbter D, Engel R, Li C, Davis JM. A meta-analysis comparing second-generation and first-generation antipsychotics for schizophrenia. Lancet 2009;373:31-41.
66. Lieberman JA, Stroup TS, McEvoy JP. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine 2005;353:1209-23.
67. Lohse MJ, Lorenzen A, Müller-Oerlinghausen B. Psychotropic drugs [Psychopharmaka]. Arzneimittel Verordnungs Report 2005:820-64.
68. Marshall M, Lockwood A, Bradley C, Adams C, Joy C, Fenton M. Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. British Journal of Psychiatry 2000;176:249-52.
69. Marwaha S, Johnson S. Schizophrenia and employment ? a review. Social Psychiatry and Psychiatric Epidemiology 2004;39:337-49.
70. Schulz KF, Altman DG, Moher D. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. BMJ 2010;340(c332):698-702.
71. Overall JE, Gorham DR. The brief psychiatric rating scale. Psychological Reports 1962;10:799-12.
72. Rathbone J, McMonagle T. Pimozide for schizophrenia or related psychoses. Cochrane Database of Systematic Reviews 2007, Issue 3. [DOI: 10.1002/14651858.CD001949.pub2].
73. Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, Guyatt GH. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Collaboration, 2008:359-83.
74. Seeman P, Lee T. Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons. Science 1975;188:1217-9.
75. Tardy M, Leucht S, Potapov A, Engel R, Dold M, Kissling W. Flupenthixol versus low-potency first generation antipsychotic drugs for schizophrenia. Cochrane Database of Systematic Reviews 2011, Issue 8. [DOI: 10.1002/14651858.CD009227].
76. Tardy M, Leucht S, Potapov A, Engel R, Huhn M, Kissling W. Fluphenazine versus low-potency first generation antipsychotic drugs for schizophrenia. Cochrane Database of Systematic Reviews 2011, Issue 8. [DOI: 10.1002/14651858.CD009230].
77. Tardy M, Leucht S, Potapov A, Kissling W, Engel R, Huhn M, et al.Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia. Cochrane Database of Systematic Reviews 2011, Issue 8. [DOI: 10.1002/14651858.CD009268].
78. Tardy M, Leucht S, Potapov A, Engel R, Huhn M, Kissling W. Perphenazine versus low-potency first generation antipsychotic drugs for schizophrenia. Cochrane Database of Systematic Reviews 2011, Issue 10. [DOI: 10.1002/14651858.CD009369].
79. Trikalinos TA, Churchill R, Ferri M, Leucht S, Tuunainen A, Wahlbeck K, et al.EU-PSI project. Effect sizes in cumulative meta-analyses of mental health randomized trials evolved over time. Journal of Clinical Epidemiology 2004;57(11):1124-30.
80. Tsuang MT. Suicide in schizophrenics, manics, depressives, and surgical controls: a comparison with general population suicide mortality. Archives of General Psychiatry 1978;35:153-5.
81. Wing JK. A simple and reliable subclassification of chronic schizophrenia. Journal of Mental Science 1961;107:862-75.
82. Xia J, Adams CE, Bhagat N, Bhagat V, Bhoopathi P, El-Sayeh H, et al.Loss to outcomes stakeholder survey: the LOSS study. Psychiatric Bulletin 2009;33(7):254-7.